Get the latest news on immunotherapy

August 18, 2024

Propensity to severe immune-related adverse events with immunotherapy: is there a genetic connection?

While immunotherapy shows remarkable results in treating skin cancer, the burden of immune-related adverse events (irAEs) is a factor to weigh when considering the use of these regimens, particularly in the adjuvant and neoadjuvant settings. Why do some patients experience severe irAEs with immunotherapy? In a recent paper, researchers at NYU Langone identified a gene signature ( ie, enrichment in a gene called spleen tyrosine kinase) in immune cells at baseline in patients who experienced severe irAEs after receiving ipilimumab /nivolumab in the post-surgical setting. Efforts like this to find biomarkers to support therapeutic decision making regarding immunotherapy are critical to optimize outcomes.

June 6, 2024

Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers

May 9, 2024

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

February 29, 2024

Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study

February 2, 2024

A new type of immunotherapy: MSK’s Christopher Klebanoff is fighting cancer cells from the inside out with T Cell Receptor (TCR) therapy

December 19, 2023

TILT Biotherapeutics announces positive clinical data in checkpoint resistant metastatic melanoma phase I trial at ESMO Immuno-Oncology 2023

December 6, 2023

Addition of navitoclax to dabrafenib/trametinib aims to improve efficacy of targeted therapy in BRAF+ Metastatic Melanoma

August 15, 2023

Merck and Moderna initiate phase 3 study evaluating V940 (mRNA-4157) in combination with KEYTRUDA® (pembrolizumab) for adjuvant treatment of patients with resected high-risk(Stage IIB-IV) melanoma

July 24, 2023

First-Line, Fixed-Duration Nivolumab plus Ipilimumab followed by Nivolumab in clinically diverse patient populations with unresectable Stage III or IV Melanoma: CheckMate 401

June 6, 2023

U.S. Food and Drug Administration accepts Bristol Myers Squibb’s supplemental biologics license application and European Medicines Agency validates application for Opdivo (nivolumab) ….

February 22, 2023

Nivolumab and Relatlimab in patients with advanced melanoma that had progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: results from the Phase I/IIa RELATIVITY-020 Trial

February 10, 2023

Low-Dose Nivolumab plus chemotherapy an accessible alternative to full-dose checkpoint inhibitors in head and neck cancers

January 10, 2023

Immunotherapy makes major strides for first-line treatment of unresectable locally advanced or metastatic esophageal squamous cell carcinoma

December 16, 2022

Risk of side effects from cancer immunotherapy linked to genetics

December 15, 2022

PD-L1 status could help inform patient selection for IO-based therapy in HNSCC

December 8, 2022

Instil Bio announces prioritization of genetically engineered CoStAR-TIL Program with ITIL-306 in advanced solid tumors and reduction in workforce

December 6, 2022

New published study further demonstrates the ability of Natera’s mPCR technology to monitor immunotherapy response in metastatic uveal melanoma patients

November 16, 2022

Iovance Biotherapeutics anounces updated clinical data for Lifileucel in advanced melanoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 28, 2022

Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma

October 18, 2022

Tebentafusp-tebn use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal Melanoma

October 17, 2022

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

October 14, 2022

Bristol Myers Squibb receives European Commission approval for LAG-3-blocking antibody combination, Opdualag (nivolumab and relatlimab), for the treatment of unresectable or metastatic mMelanoma with tumor cell PD-L1 Expression < 1%

September 15, 2022

Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial

September 15, 2022

Bristol Myers Squibb announces adjuvant treatment with Opdivo (nivolumab) demonstrated statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) in patients with Stage IIB/C Melanoma in the CheckMate -76K trial

September 14, 2022

Regeneron, Immutep talk LAG-3 as ESMO highlights new I-O approaches

September 12, 2022

Positive neoadjuvant Libtayo® (Cemiplimab) monotherapy data in resectable cutaneous squamous cell carcinoma presented at ESMO and published in NEJM

September 12, 2022

Fianlimab (LAG-3 Inhibitor) combined with Libtayo® (CemiIpliImab) demonstrates greater than 60% response rates in two independent cohorts of patients with advanced melanoma naïve to PD-1 or PD-L1 Inhibitors

September 12, 2022

Immunotherapy before surgery boosts survival in skin cancer

September 11, 2022

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

September 9, 2022

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response

September 6, 2022

Bristol Myers Squibb receives positive CHMP opinion recommending approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for treatment of patients with unresectable or metastatic melanoma

July 20, 2022

Merck receives positive EU CHMP opinion for KEYTRUDA® (pembrolizumab) as adjuvant treatment for adult and adolescent (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection

May 18, 2022

BIO Biotech announces initiation of phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma

May 16, 2022

Replimune provides new clinical data, broad program update and future development strategy for its tumor-directed oncolytic immunotherapies

March 30, 2022

Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC) | BioSpace

March 15, 2022

Merck announces KEYLYNK-010 trial evaluating KEYTRUDA® (pembrolizumab) in combination with LYNPARZA® (olaparib) in patients with metastatic Castration-resistant prostate cancer to stop for futility

March 15, 2022

Relatlimab/Nivolumab Combo Continues to Impress in Previously Untreated Metastatic or Unresectable Melanoma

March 15, 2022

Plasmid DNA vaccine candidate’s phase 1 study targets rare but aggressive form of skin cancer

March 14, 2022

Bristol Myers Squibb and Nektar announce update on phase 3 PIVOT IO-001 trial evaluating Bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma

March 13, 2022

Researchers uncover immune environment of rare type of melanoma

March 11, 2022

New research seeks to incorporate immunotherapy into early lines of ESCC treatment

March 3, 2022

Genome and Company announces Clinical Trial Collaboration with MSD to evaluate ‘GEN-001’ in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients

February 22, 2022

Long-term follow-up data reinforce continued overall survival benefit of BAVENCIO® (avelumab) first-line maintenance treatment in patients with advanced urothelial carcinoma

February 17, 2022

Study finds early signs of response to immunotherapy for melanoma in blood

February 17, 2022

Vitiligo from checkpoint inhibitors not limited to melanoma

February 16, 2022

Progress in study combining PD-1 inhibitor pembrolizumab and anti-inflammatory drug vilobelimab in squamous cell skin cancer

February 15, 2022

Combination cancer immunotherapy with dendritic cell vaccine and nanoparticles loaded with interleukin-15 and anti-beta-catenin siRNA significantly inhibits cancer growth and induces anti-tumor immune response

February 15, 2022

Potential use of FDG-PET findings in reducing duration of immunotherapy in patients with advanced melanoma

February 15, 2022

Prognostic impact of baseline neutrophil-to-eosinophil ratio in patients with metastatic renal cell carcinoma treated with nivolumab therapy in second or later lines

February 15, 2022

Early studies investigate novel vaccine strategy in Merkel cell carcinoma

February 14, 2022

Avalon GloboCare expands its cellular immuno-oncology platform with the addition of novel chimeric antigen receptor-natural killer (CAR-NK) cell therapies

February 14, 2022

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma

February 7, 2022

Eisai: Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) approved in Taiwan for the first-line treatment of patients with advanced renal cell carcinoma

January 29, 2022

Longer follow-up shows improved disease-free survival with nivolumab in patients with high-risk muscle-invasive urothelial carcinoma (MIUC)

January 26, 2022

Selecting treatment options for relapsed/refractory multiple myeloma

January 26, 2022

FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma

January 26, 2022

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology

January 26, 2022

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

January 25, 2022

OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi® after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients

January 24, 2022

First-in-human trial with CAR macrophages shows promise targeting solid tumors

January 22, 2022

Updated CheckMate 649 results show sustain benefit of nivolumab plus chemo for gastric/GEJ cancer

January 20, 2022

Results from pivotal phase 3 KEYNOTE-775/Study 309 trial of KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) in advanced endometrial carcinoma published in the New England Journal of Medicine

January 19, 2022

23andMe details genetically informed cancer immunotherapy development plans

January 18, 2022

Evaxion Biotech receives regulatory clearance to initiate phase 2 trial of EVX-01 in combination with KEYTRUDA® for treatment of melanoma

January 16, 2022

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

January 14, 2022

Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: Real-world data assessment

January 13, 2022

A lower dose of Xpovio (selinexor) may help patients with myeloma get the ‘full benefit of the drug’

January 13, 2022

Nivolumab achieves durable responses and extends OS versus sorafenib in HCC

January 13, 2022

Adagene : Announces first patients with advanced non-small cell lung cancer dosed in phase 1b/2 clinical trial of ADG106 in combination with nivolumab in Singapore

January 12, 2022

Biomica announces clearance for first-in-human phase I study of BMC-128 in combination with Bristol Myers Squibb’s anti-PD-1 Opdivo®

January 12, 2022

IMV announces first patient dosed in the VITALIZE Phase 2B clinical study evaluating its lead compound, MVP-S, in combination with KEYTRUDA® (pembrolizumab) in patients with relapsed/refractory diffuse large B cell lymphoma

January 11, 2022

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

January 11, 2022

Study: Relatlimab, nivolumab improve progression-free survival in metastatic melanoma

January 10, 2022

BioAtla announces clinical collaboration with Bristol Myers Squibb to study mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) in combination with Opdivo® (nivolumab) for treatment of solid tumors

January 7, 2022

Inhibrx announces initial phase 1 dose escalation results for INBRX-106, a novel hexavalent OX40 agonist, in combination with Keytruda® (pembrolizumab) for NSCLC and melanoma patients

January 4, 2022

Vaccinex reports phase Ib KEYNOTE B84 combination study of Keytruda® and pepinemab in patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) passes planned interim safety analysis

January 4, 2022

Vaccinex reports phase Ib KEYNOTE B84 combination study of Keytruda® and pepinemab in patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) passes planned interim safety analysis

January 3, 2022

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) approved in Japan for patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy

December 22, 2021

Merck receives positive EU CHMP opinion for KEYTRUDA® (pembrolizumab) as adjuvant therapy for certain patients with renal cell carcinoma following surgery

December 17, 2021

Antengene presents results of Phase 1b TOUCH Trial of selinexor for the treatment of T and NK-cell lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody

December 8, 2021

PD-L1 cutoff for TNBC Keytruda benefit confirmed in KEYNOTE analyses, but questions linger

December 8, 2021

Which patients benefit most from immunotherapy? This tool can tell

December 7, 2021

IDEAYA reports clinical data from Phase 2 expansion dose of darovasertib and crizotinib synthetic lethal combination in heavily pre-treated metastatic uveal melanoma

December 6, 2021

Merus presents clinical data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

December 3, 2021

FDA approves Merck’s KEYTRUDA® (pembrolizumab) as adjuvant treatment for adult and pediatric (≥12 years of age) patients with Stage IIB or IIC melanoma following complete resection

December 2, 2021

European Commission Approves KEYTRUDA® Plus LENVIMA® as First-Line Treatment for adult patients with advanced renal cell carcinoma

November 22, 2021

Antengene announces IND approval in China for a phase I/II study of selinexor (ATG-010) in patients with non-Hodgkin lymphoma

November 18, 2021

FDA approves Mercks KEYTRUDA (pembrolizumab) as adjuvant therapy for certain patients with renal cell carcinoma (RCC) following surgery

November 17, 2021

OSE Immunotherapeutics Randomizes First Patient to Phase II Trial of Vaccine in Metastatic NSCLC

November 15, 2021

OSE Immunotherapeutics presented the first positive preclinical efficacy data on CLEC-1, a novel myeloid immune checkpoint target for cancer immunotherapy

November 15, 2021

Coherus and Junshi Biosciences announced that the FDA accepted their Biological License Application for toripalimab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma

November 9, 2021

An international phase III study compared treatment outcomes between once-weekly selinexor plus bortezomib-dexamethasone, and twice-weekly bortezomib-dexamethasone alone in patients with multiple myeloma

November 9, 2021

Antengene to release preliminary results of selinexor for the treatment of peripheral t-cell lymphoma and nk/t-cell lymphoma at the 2021 ASH Annual Meeting

November 9, 2021

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

November 6, 2021

Early safety monitoring critical with lenvatinib/pembrolizumab in kidney cancer

November 3, 2021

Alpha Tau announces enrollment of first patient in combination trial of Alpha DaRT™ and pembrolizumab (Keytruda®) for the treatment of recurrent unresectable or metastatic squamous cell carcinoma of the head and neck

November 3, 2021

The FDA has accepted Memgen’s investigational new drug (IND) application for MEM-288, the company’s immunotherapy candidate for the treatment of multiple solid tumors

November 1, 2021

Antengene Corporation Limited announced that China’s National Medical Products Administration (NMPA) has approved an open-label Phase Ib dose-escalation study designed to assess the safety of ATG-008 (onatasertib) in combination with ATG-010 (selinexor) in patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL)

October 31, 2021

KEYTRUDA continued to improve Recurrence-Free Survival (RFS) compared to placebo as adjuvant therapy for patients with resected stage IIB or IIC melanoma at 2nd interim analysis of phase 3 KEYNOTE-716 trial

October 26, 2021

Evaxion Biotech announces clinical collaboration to evaluate lead product candidate with KEYTRUDA® (pembrolizumab) in patients with melanoma

October 24, 2021

New study offers possible immunotherapy breakthrough for cancer

October 22, 2021

The European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC) whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5

October 22, 2021

The European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1

October 22, 2021

Neoadjuvant talimogene laherparepvec (T-VEC) followed by surgery significantly improved survival when compared with surgery alone in patients with advanced, resectable melanoma

October 21, 2021

Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer.

October 21, 2021

Antengene enters into a research collaboration and license option agreement with LegoChem Biosciences for new antibody-drug conjugate candidates

October 21, 2021

Ultimovacs receives dual FDA Fast Track Designation for UV1 in advanced malignant melanoma

October 20, 2021

GenFleet Therapeutics announced that the first patient with metastatic sigmoid adenocarcinoma has been dosed in a phase Ib/II trial of GFH018 in combination with toripalimab (anti-PD-1 monoclonal antibody) as part of global multi-center clinical research.

October 20, 2021

NeoTx Therapeutics, a clinical-stage immuno-oncology company, announced today that the first patient has been enrolled in the company’s phase 2a clinical trial of naptumomab estafenatox (NAP), its lead Tumor Targeted Superantigen (TTS) candidate, in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).

October 20, 2021

A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity

October 20, 2021

Merck KGaA taps CytoReason’s machine learning platform to profile immuno-oncology drug

October 19, 2021

Sarah P. Psutka, MD, discusses the efficacy of the combination of immune checkpoint inhibitor therapy plus tyrosine kinase inhibitor for the treatment of metastatic renal cell carcinoma

October 19, 2021

Defence Therapeutics scores again with new planned phase 1 trial evaluating its DC cancer vaccine candidate AccuVAC-D002 against melanoma

October 18, 2021

ctDNA reduction after tebentafusp predicts OS in uveal melanoma

October 11, 2021

Kintor Pharmaceutical Limited announces China NMPA approves clinical trial of ALK-1 and nivolumab combination therapy for the first-line treatment of advanced hepatocellular carcinoma

October 11, 2021

CatalYm presents updated tolerability and preliminary pharmacodynamics data from the first-in-human trial of CTL-002 in monotherapy and in combination with nivolumab

October 10, 2021

A subset of patients with metastatic uveal melanoma achieved promising responses after treatment with entinostat and pembrolizumab.

September 28, 2021

FDA Accepts Bristol Myers (BMY) supplemental biologics license applications for two combinations with Opdivo for esophageal squamous cell carcinoma

September 28, 2021

Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors

September 28, 2021

Keytruda Meets Endpoints in KEYNOTE Trial, Treatment of Hepatocellular Carcinoma

September 28, 2021

FDA grants priority review to Libtayo for advanced cervical cancer

September 27, 2021

Startup company Accession Therapeutics Ltd. hopes to develop the first oncolytic virus to be genetically engineered to exclusively infect cancer cells

September 25, 2021

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma

September 24, 2021

First patient with lung cancer treated in phase 2b tomivosertib trial

September 23, 2021

Eisai and Merck present first-time data from two studies evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) in seven different tumor types at ESMO Virtual Congress 2020

September 23, 2021

Alrizomadlin Granted FDA Fast Track Designation for Relapsed/Refractory Unresectable or Metastatic Melanoma

September 22, 2021

HUTCHMED has initiated a phase III study, SURTORI-01, to evaluate the efficacy and safety of surufatinib in combination with toripalimab for patients with advanced neuroendocrine carcinoma

September 20, 2021

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

September 19, 2021

Nivolumab/rucaparib combination induces clinically effective outcomes in patients with metastatic castration resistant prostate cancer who are HRD-positive in CheckMate 9KD trial

September 18, 2021

Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma [ESMO Congress 2021 Press Release]

September 16, 2021

Phase ½ investigator-sponsored trial launched to investigate evorpacept (ALX148) in combination with rituximab and lenalidomide for the treatment of patients with indolent and aggressive non-Hodgkin lymphoma

September 15, 2021

BioNTech wins FDA’s orphan drug status for melanoma candidate

September 15, 2021

Pulmocide’s lead drug candidate opelconazole (PC945) has been granted Orphan Drug, Fast Track, and Qualified Infectious Disease Product Designations for the treatment of invasive pulmonary aspergillosis by the FDA

September 14, 2021

Aprea to present phase 1/2 trial data of eprenetapopt-Keytruda combo to treat tumors

September 13, 2021

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update

September 13, 2021

Instil Bio to Begin Phase II Trial of TIL Therapy for Advanced Melanoma

September 12, 2021

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

September 12, 2021

Study shows durable remissions with the combination of pembrolizumab and chemotherapy in patients with EGFR/ALK-positive non-small cell lung cancer

September 9, 2021

Karyopharm Therapeutics Inc is recruiting patients for a study investigating selinexor in combination with pembrolizumab for the treatment of locally advanced or metastatic melanoma

September 8, 2021

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers

September 4, 2021

Keytruda receives full FDA approval for bladder cancer

September 2, 2021

Certain Genomic Pathways of Gut Microbiome Significantly Associated With Survival in Nivolumab-Treated Patients With Gastric/GEJ Cancer

September 1, 2021

Dysregulation of group 3 innate lymphoid cells (ILC3s) unleashes progression and immunotherapy resistance in colon cancer

August 17, 2021

European Medicines Agency validates Bristol Myers Squibb’s Applications for Opdivo + Yervoy and Opdivo + chemotherapy as first-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma

August 16, 2021

Phase II findings for nivolumab plus ipilimumab for metastatic castration resistant prostate cancer warrants further study

August 16, 2021

Combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma (CHOPIN): Study protocol for a phase Ib/randomized phase II trial

August 10, 2021

FDA accepts two applications for expanded Keytruda use

August 9, 2021

Keytruda approved to treat high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment

August 5, 2021

Merck’s Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers

August 5, 2021

Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial

August 2, 2021

Ipilimumab plus nivolumab improves survival in melanoma with brain metastases

August 2, 2021

FDA grants Fast Track Designation to nemvaleukin alfa for mucosal melanoma

July 28, 2021

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

July 28, 2021

NOXXON Pharma enters second clinical collaboration with MSD to evaluate NOX-A12 in combination with Keytruda in upcoming phase 2 pancreatic cancer study

July 16, 2021

Bristol Myers Squibb’s Opdivo and Yervoy combo falls short in first-line squamous head and neck cancer

July 14, 2021

Regorafenib/nivolumab elicits better responses in patients without liver metastases in mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

July 14, 2021

Combination of pembrolizumab and low-dose ipilimumab appeared to show significant antitumor activity among patients with advanced melanoma who previously failed immunotherapy

July 11, 2021

Cabozantinib fails to improve progression-free survival and results in more adverse effects in patients with renal cell carcinoma

July 9, 2021

Alpine Immune Sciences to collaborate with Merck on immune-oncology study to evaluate ALPN-202 in combination with Keytruda (pembrolizumab)

June 29, 2021

Corbus Pharmaceuticals announces topline results from DETERMINE Phase 3 study of lenabasum for treatment of dermatomyositis

June 23, 2021

Rubius Therapeutics announces first patient dosed with RTX-240 in combination with Keytruda in ongoing Phase ½ clinical trial for the treatment of advanced solid tumors

June 23, 2021

Patients with advanced esophageal squamous cell carcinoma experience improved survival outcomes with addition of nivolumab to ipilimumab or chemotherapy

June 21, 2021

Nivolumab/ipilimumab triplet improves OS in advanced non-small cell lung cancer compared with chemotherapy alone

June 18, 2021

A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1

June 17, 2021

Merck’s KEYNOTE-564 data heralds early adjuvant Keytruda use in renal cancer

June 16, 2021

ODAC panel approves 4 of 6 anti-PD-1/PD-L1 drugs in accelerated approval program

June 15, 2021

Linnaeus Therapeutics announces expanded clinical collaboration with Merck to include multiple additional cohorts to evaluate LNS8801 in combination with Keytruda in patients with advanced cancer

June 14, 2021

Istari Oncology announces FDA granted fast track designation to PVSRIPO for the treatment of advanced melanoma

June 14, 2021

Exelixis announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate XL092 in combination with immune-oncology therapies in advanced solid tumors

June 11, 2021

APG-115 plus pembrolizumab safe with preliminary efficacy in unresectable or metastatic melanoma or advanced solid tumors

June 7, 2021

Positive preliminary results from Delcath Systems’ FOCUS trial presented at the 2021 ASCO annual meeting

June 7, 2021

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

June 7, 2021

An overview of the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer

June 7, 2021

NeoImmune Tech trial data evaluating NT-I7 in combination with pembrolizumab as a treatment for advanced solid tumors presented at ASCO annual meeting

June 7, 2021

Surface Oncology to collaborate with Roche on immune-oncology study evaluating SRF388, targeting IL-27, as part of a novel combination in patients with advanced treatment-naïve hepatocellular carcinoma

June 4, 2021

Coherus and Junshi Biosciences announce toripalimab in combination with chemotherapy met primary progression free survival (PFS) endpoint as first line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)

June 4, 2021

Alkermes results presented at ASCO 2021 show a dwindling response rate in melanoma patients receiving nemva monotherapy

June 4, 2021

Nanobiotix’s radiotherapy enhancer for tumors also primes the immune system

June 4, 2021

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

June 4, 2021

Results presented at Asco show a dwindling response rate in melanoma patients receiving Alkermes’ nemvaleukin monotherapy

June 4, 2021

Iovance Biotherapeutics announces clinical data for lifileucel in combination with pembrolizumab in advanced melanoma at ASCO 2021 annual meeting

June 3, 2021

Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma

June 2, 2021

Researchers have identified a protein that helps tumors evade the immune system and, in certain types of cancers, is linked to poorer chance of survival

May 28, 2021

Combination therapy with nivolumab and relatimab prolongs progression-free survival in advanced melanoma

May 25, 2021

Xilio and Merck partner on anti-CTLA-4 antibody in combination with Keytruda in solid tumors

May 24, 2021

Scopus BioPharma Inc. announced the approval of an investigational new drug application by the FDA for CPG-STAT3siRNA, an immune-oncology RNA therapy for the treatment of multiple cancers

May 21, 2021

Japan’s Astellas Pharma and US biotech Seagen have announced updated results from clinical trials evaluating Padcev in combination with Keytruda in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy

May 21, 2021

Trial data shows durable, long-term survival with nivolumab, ipilimumab in patients with non-small cell lung cancer with PD-L1 expression

May 21, 2021

Bristol Myers wins positive opinion in Europe for Opdivo and Yervoy combo for colorectal cancer

May 21, 2021

Boehringer Ingelheim and OSE Immunotherapeutics unveiled preliminary data from a phase 1 trial of BI 7765063 at the 2021 ASCO annual meeting

May 21, 2021

Dual immunotherapy regimen targeting novel lymphocyte-activation gene 3 (LAG-3) immune checkpoint led to a significant progression-free survival (PFS) benefit in patients with advanced melanoma

May 19, 2021

Ascentage Pharma to announce updated results demonstrating clinical potential of alrizomadlin plus pembrolizumab in patients with advanced solid tumors that had failed immunotherapies at ASCO 2021

May 19, 2021

Biomarker panels evaluated by multiplex immunoassays with high analytical performance demonstrated potential complementary values in detection of uveal melanoma

May 19, 2021

6 ½ year outcomes for Opdivo in combination with Yervoy continue to demonstrate durable long-term survival benefits in patients with advanced melanoma

May 19, 2021

Results from phase 3 KEYNOTE-522 trial showed that Keytruda met the dual-primary endpoint of event-free survival for treatment of high-risk early-stage triple-negative breast cancer patients

May 12, 2021

Exelixis’ Cabometyx scores backing from Ipsen in thyroid cancer with full data release set for ASCO

May 12, 2021

Bristol-Myers Squibb will present new data examining the combination of Opdivo plus Yervoy in various cancers in June’s American Society of Clinical Oncology (ASCO) Meeting

May 11, 2021

FDA approval summary of nivolumab plus ipilimumab for the treatments of patients with hepatocellular carcinoma previously treated with sorafenib

May 11, 2021

BostonGene and University of Pennsylvania’s Abramson Cancer Center to collaborate on immunotherapy studies

May 10, 2021

IMV Inc. announced that its lead compound, maveropepimut-S will be investigated in patients with hormone receptor positive/HER2-negative breast cancer

May 10, 2021

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients

May 7, 2021

Opdivo sBLA receives FDA acceptance and Priority Review for adjuvant treatment for patients with muscle-invasive urothelial carcinoma

May 7, 2021

New immunotherapy combinations are being explored in small cell lung cancer

May 6, 2021

Microneedles for cancer immunotherapy may lead to minimal invasiveness and side effects

May 6, 2021

Merck’s Keytruda has won FDA clearance to treat new patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma

May 6, 2021

Fusion Pharmaceuticals announces clinical collaboration with Merck to evaluate Fusion’s Targeted Alpha Therapy (TAT) in combination with Merck’s Keytruda in patients with solid tumors expressing IGF-1R

May 5, 2021

Alchemab to collaborate with AstraZeneca to use Alchemab’s Drug Discovery Platform for prostate cancer study

May 5, 2021

Checkmate Pharmaceuticals announces initiation of patient dosing in potential registration trial of Vidutolimod in patients with anti-PD-1 refractory advanced melanoma

May 5, 2021

Replimune provides a regulatory update for its registration-directed clinical trials evaluating RP! In combination with Libtayo

April 30, 2021

FDA panel denies support for maintaining Bristol’s Opdivo as liver cancer treatment

April 29, 2021

ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer

April 28, 2021

Biopharmaceuticals announces acceptance of PV-10 immunotherapy abstracts at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

April 28, 2021

Jemperli and Zynlonta have been approved by the FDA for advanced endometrial cancer and relapsed large B-cell lymphoma respectively

April 28, 2021

The virtual 2021 Great Debates and Updates in Women’s Oncology meeting presented a lively debate regarding immunotherapy for early triple-negative breast cancer (TNBC)

April 27, 2021

Alkermes initiates ARTISTRY-6 trial of nemvaleukin alfa monotherapy in patients with melanoma

April 26, 2021

Researchers have identified the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy

April 26, 2021

The FDA’s Oncologic Drugs Advisory Committee will be moving forward with a public review of 6 indications for immune checkpoint inhibitors granted under the agency’s accelerated approval process that later failed to reach thresholds for statistical significance in confirmatory clinical trials

April 23, 2021

ADC Therapeutics nabs its first approval as FDA offers a quick OK for its diffuse large B-cell lymphoma cancer treatment

April 23, 2021

GlaxoSmithKline immunotherapy Jemperli wins FDA approval for recurrent or advanced endometrial cancers with a specific type of genetic error that disrupts cells’ ability to repair DNA

April 23, 2021

Effects of Keytruda sustained after 3.5 years in high-risk stage 3 cutaneous melanoma

April 23, 2021

EU Panel recommends nivolumab/ipilimumab in frontline unresectable malignant pleural mesothelioma

April 22, 2021

Candel Therapeutics has announced it has completed enrollment for its phase I clinical trial in patients with newly diagnosed high-grade glioma to evaluate the safety and efficacy of CAN-2409 in combination with Opdivo

April 22, 2021

Adjuvant nivolumab improved disease-free survival in esophageal and gastroesophageal junction cancers with residual pathologic disease after resection

April 22, 2021

Immunotherapy combinations may hold promise in treatment of late-stage or recurrent endometrial cancer

April 22, 2021

Toripalimab plus chemotherapy as first-line treatment for advanced esophageal cancer reached primary endpoints in phase III clinical study

April 21, 2021

Opdivo has been granted an extended indication for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma

April 21, 2021

Istari Oncology announces publication of “A phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma” in the BMJ’s Journal for ImmunoTherapy of Cancer

April 16, 2021

IDEAYA reports clinical data from the ongoing phase 1/2 trial evaluating darovasertib monotherapy and binimetnib combination therapy in patients with solid tumors, including metastatic uveal melanoma and skin melanoma

April 15, 2021

AACR Forum Microbiome Pandemonium: Checkpoints and the Microbiome discusses growing evidence for the relationship between gut microbiota and the response of immune checkpoint inhibitors

April 14, 2021

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announced that three projects have been selected to study oral decitabine and cedazuridine

April 14, 2021

A new phase I study at the Memorial Sloan Kettering Cancer Center plans to assess the safety of RO7293583 immunotherapy in patients with metastatic melanoma that contains a protein called TYRP1

April 14, 2021

Panel discusses how combination therapies could create better, longer-lasting outcomes

April 13, 2021

The AACR’s Presidential Address, Fighting Melanoma with the Immune System, discussed how researchers are working to change the treatment paradigm for patients with melanoma through next-generation techniques that stimulate immune response and amplify antitumor activity

April 12, 2021

Forum considers when the right time is to utilize CAR-T therapies

April 11, 2021

First Clinical Trials Plenary features practice-changing data from phase III trials

April 10, 2021

Results from the AACR annual meeting show that patients with early-stage non-small cell lung cancer who took a combination of Opdivo and chemotherapy before surgery were nearly 14 times more likely to show no signs of cancer cells in their resected tissue compared with those who got chemo alone

April 10, 2021

A liquid biopsy test to assess plasma cell-free DNA integrity could improve the accuracy of magnetic resonance imaging for predicting the achievement of complete response among patients with locally advanced breast cancer who had received neoadjuvant chemotherapy, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021

April 10, 2021

Copanlisib-rituximab combination cuts lymphoma progression or death by nearly half in CHRONOS-3 trial

April 10, 2021

Neoadjuvant nivolumab plus chemotherapy increased pathological complete response rate in CheckMate-816 lung cancer trial

April 9, 2021

Case report describes myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis

April 9, 2021

The National Institute for Health and Care Excellence (NICE) has issued a preliminary no for NHS use of Bristol-Myers Squibb’s Opdivo/Yervoy combination for treating metastatic non-small-cell lung cancer

April 8, 2021

Merck announced that Keytruda has succeeded in a phase 3 trial in early kidney cancer

April 8, 2021

University of Texas MD Anderson Cancer Center and TriSalus Life Sciences announce collaboration on studies evaluating the administration of investigational SD-101 intravascularly via the FDA cleared Pressure-Enabled Drug Delivery (PEDD) technology across a range of liver and pancreatic solid tumors

April 8, 2021

Merck’s Keytruda demonstrated superior disease-free survival compared with placebo as adjuvant therapy in patients with renal cell carcinoma following surgery

April 7, 2021

PsiOxus Therapeutics updates agreement with Bristol Myers Squibb to advance their clinical stage immune-oncology collaboration to investigate the combination of NG-641 with Opdivo in several tumor types

April 1, 2021

Phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma finds talimogene laherparepvec upregulates immune-cell populations in non-injected lesions

March 30, 2021

Huyabio International announces Phase 3 global clinical trial collaboration with Bristol Myers Squibb for subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy

March 30, 2021

LATTICE radiotherapy plus immunotherapy shows promise in treating advanced bulky tumors

March 29, 2021

FDA issues a complete response letter (CRL) to Merck’s Keytruda for triple-negative breast cancer

March 26, 2021

Phase 2b VITAL study of gemogenovatucel-T immunotherapy demonstrates clinical benefit in homologous recombination proficient ovarian cancer

March 25, 2021

Bristol Myers Squibb announces RELATIVITY-047, a trial evaluating Anti-LAG-3 antibody relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma

March 25, 2021

Immuno-oncology treatments finding success with Combination Therapies

March 25, 2021

Chronic immune-related adverse events appeared more common than previously thought after adjuvant anti-PD-1 immunotherapy for stage III to stage IV melanoma according to study published in JAMA Oncology

March 24, 2021

Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

March 24, 2021

Adjuvant nivolumab improves disease-free survival in resected esophageal/gastroesophageal junction cancer according to phase III CheckMate 577 trial

March 22, 2021

Eucure Biopharma announces that its anti-CTLA-4 antibody (YH001) in combination with Junshi Biosciences’ TUOYI has demonstrated encouraging anti-tumor activity in Phase I trial

March 19, 2021

Noxopharm commences IONIC immune-oncology trial to test Veyonda and Opdivo combination against a range of tumor types

March 19, 2021

Merck and Eisai’s Keytruda-Lenvima Combo significantly improved progression-free survival in advanced endometrial cancer.

March 19, 2021

Phase II trial announced for regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma

March 18, 2021

Tilsotolimod plus Yervoy combo fails in anti-PD-1 refractory melanoma study

March 14, 2021

FDA evaluates status of 6 cancer drug indications that were granted accelerated approvals

March 12, 2021

AVEO Oncology announces collaboration with Bristol Myers Squibb to evaluate tivozanib and nivolumab combination for advanced relapsed or refractory renal cell carcinoma

March 11, 2021

Researchers at Moffitt Cancer Center suggests that sequential administration of immunotherapy followed by targeted therapy prolongs anti-tumor responses in preclinical models

March 2, 2021

Merck & Co. voluntarily withdraws Keytruda’s indication in third-line small cell lung cancer

March 2, 2021

Phase III CONFIRM trial suggests effective use of Opdivo after chemotherapy for malignant pleural mesothelioma

March 2, 2021

Opdivo-Yervoy combination plus two cycles of platinum doublet chemotherapy shows significant improvement in survival of patients with advanced non-small cell lung cancer

March 1, 2021

Researchers at Columbia and MIT created a new technique called Perturb-CITE-sequencing to identify previously unknown resistance mechanisms to immune checkpoint inhibitors in melanoma patients

March 1, 2021

Researchers target p53 and RAS proteins in cancer immunotherapy using bispecific antibodies to curb tumor growth

February 26, 2021

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo in combination with Cabometyx for the first-line treatment of adults with renal cell carcinoma to be reviewed by the European Commission (EC)

February 25, 2021

Compugen reports encouraging results from their phase I study of COM701 monotherapy and in combination with Opdivo for various types of cancers

February 23, 2021

NeoImmuneTech receives U.S. FDA Investigational New Drug Clearance for Pilot Study of NT-17 (efineptakin alfa) for Progressive Multifocal Leukoencephalopathy

February 22, 2021

Cemiplimab approved as front-line therapy for advanced NSCLC

February 22, 2021

FDA grants Fast Track Designation to GEN-1 immunotherapy for patients with advanced stage III or IV ovarian cancer

February 22, 2021

AstraZeneca to withdraw Imfinzi in advanced bladder cancer treatment in the U.S. after confirmatory trial showed no improvement of Imfinzi checkpoint inhibitor use over chemotherapy

February 20, 2021

Australian researchers identify protein linked to better patient responses to checkpoint inhibitor immunotherapy

February 19, 2021

Immunocore’s novel bispecific protein, tebentafusp, granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA for uveal melanoma

February 18, 2021

New trial funding for Nektar Therapeutics’ bempegaldesleukin drug paired with Merck’s pembrolizumab for squamous cell carcinoma of the head and neck

February 18, 2021

Study findings by researchers at Memorial Sloan Kettering Cancer Center suggest that blocking cancer cells’ use of sugar could increase the effectiveness of immunotherapy

February 18, 2021

Phase III OlympiA trial investigating effect of PARP inhibitor Lynparza shows positive results in adjuvant setting for patients with early breast cancer

February 17, 2021

Immunitas Therapeutics uses single-cell RNA-sequencing to identify the NK gene KLRB1 as a candidate inhibitory receptor on NK and T cells with applicability as a target in cancer immunotherapy

February 17, 2021

Research suggests that cosmetic lasers may make immune checkpoint inhibitors more effective in treating cancers with low mutation numbers

February 17, 2021

Phase 2 of neoadjuvant tavokinogene teleplasmid plus nivolumab study doses first patient with operable, locally or regionally advanced melanoma before surgery

February 16, 2021

Immunotherapy-docetaxel combinations show promise in metastatic castration-resistant prostate cancer

February 16, 2021

Study findings indicate promising use of cord blood-derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma

February 15, 2021

Ludwig Cancer Research study identified novel mechanism for cancer immunotherapy using cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade to disable suppressive immune cells

February 15, 2021

Study from the University of Pittsburgh School of Medicine suggests MCT1 inhibition drugs may boost effects of cancer immunotherapy

February 15, 2021

FDA approves nivolumab-cabozantinib as first-line treatment of advanced renal cell carcinoma

February 11, 2021

Repertoire Immune Medicines and Dana-Farber Cancer Institute announce new research collaboration aimed to identify novel tumor antigen targets relevant to HPV+ head and neck tumors

February 10, 2021

Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

February 10, 2021

FDA ODAC votes against recommending Keytruda for breast cancer

February 10, 2021

Case study analyzes successful Nivolumab treatment for head and neck squamous cell carcinoma after allogeneic bone marrow transplantation

February 10, 2021

FDA approves the chimeric antigen receptor (CAR) T-cell therapy Breyanzi, lisocabtagene maraleucel, for large B-cell lymphomas

February 10, 2021

Targovax and Papyrus will run pre-clinical research to evaluate the feasibility of combining Oncolytic Virus (ONCOS) and Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML) tumor suppressor technology

February 10, 2021

4D pharma announces new clinical trial using combined MRx0518, a Live Biotherapeutic product, and BAVENCIO monotherapies for locally advanced or metastatic urothelial carcinoma

February 8, 2021

Combination of Keytruda and Yervoy fails to prolong survival and delay disease progression of advanced non-small cell lung cancer

February 8, 2021

Joint radionuclide and immunotherapy approach for prostate cancer effective in mice

February 8, 2021

Multigene variant profiling assay to guide targeted immunotherapy selection in solid tumors

January 25, 2021

Korea-based microbiome technology company, Genome & Company, utilizes microbiome-based drugs in combination with Merck and Pfizer’s Bavencio in new U.S. clinical trials

January 13, 2021

The Society for Immunotherapy of Cancer (SITC) recommends actions for patients concerning SARS-CoV-2 vaccination and cancer immunotherapy

December 10, 2020

Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer Symposium

December 9, 2020

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

November 13, 2020

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

November 6, 2020

ESMO 2020 Virtual Conference: Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

September 21, 2020

ESMO 2020 Virtual Conference: QUANTITATIVE SUMMARY OF QOL DATA CONFIRMS IMMUNE CHECKPOINT INHIBITOR THERAPY IS GENERALLY WELL-TOLERATED

September 21, 2020

ESMO Virtual Conference 2020: IMMUNOTHERAPY IS BENEFICIAL IN GASTRIC AND ESOPHAGEAL CANCERS, STUDIES SHOW

September 20, 2020

ESMO 2020 Virtual Conference: PEMBROLIZUMAB DELIVERS CLINICAL BENEFIT IN SELECTED HISTOTYPES OF RARE SARCOMA

September 19, 2020

ESMO 2020 Virtual Conference: Results for Sacituzumab govitecan-hziy in breast and bladder support this antibody-drug conjugate

September 19, 2020

ESMO Virtual Conference 2020: Results from IO Therapy for Triple Negative Breast Cancer

September 19, 2020

ESMO Virtual Conference 2020: Nivolumab and cabozantinib effective in first-line treatment for metastatic kidney cancer

September 18, 2020

Durvalumab demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years

September 18, 2020

2020 ESMO Virtual Congress 2020: Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO

September 17, 2020

ESMO Virtual Congress 2020: Nivolumab + Ipilimumab vs. Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma in CheckMate 214: 4-Year Follow-up and Subgroup Analysis of Patients without Nephrectomy

September 14, 2020

Personalized treatment strategies in melanoma could reduce toxicity burden from immunotherapy without compromising benefits

June 3, 2020

Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1

May 28, 2020

Immunotherapy Avelumab Shows Potential in Rare Gynecologic Cancer Resistant to Chemotherapy

May 28, 2020

Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With Specific DNA Mutations

May 18, 2020

FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup

April 28, 2020

FDA Approves Every-6-Week Pembrolizumab Dosage

April 27, 2020

Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six Weeks (Q6W) Comparable to Approved 200 mg Every Three Weeks (Q3W) Regimen

April 27, 2020

Seattle Cancer Care Alliance, at the epicenter of the US epidemic, provides insights for cancer care during the evolving the COVID-19 crisis.

February 12, 2020

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)

February 12, 2020

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

January 23, 2020

FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancers

January 15, 2020

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer

January 13, 2020

Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

December 9, 2019

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)

December 8, 2019

IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer

October 28, 2019

Nivolumab more effective versus investigator’s choice in younger vs older patients with recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)

September 4, 2019

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled, phase 3 trial

August 16, 2019

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma

August 16, 2019

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

May 22, 2019

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)

April 16, 2019

AACR 2019 Research Roundup: Pancreatic Cancer Immunotherapy, Prostate Cancer Drug Resistance, Insight into Inherited Cancer Mutations

March 30, 2019

Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma

February 13, 2019

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

February 8, 2019

Generex Biotechnology Signs Clinical Trial Agreement with the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer

11/27/2018

Case study shows metastatic urothelial carcinoma patient with gastritis infection after receiving atezolizumab then pembrolizumab

09/28/2018

FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma

10/24/2017